Zhejiang Kang En Bishe Pharmaceutical Co., Ltd. is the holding subsidiary of Kang Enbei Group Co., Ltd.. It was formerly known as the "Lanxi Yunshan Pharmaceutical Factory" founded in 1969. After more than 30 years of development, it has grown into a family to implement the entire industry.Chain operation, large -scale pharmaceutical listed enterprises integrating medicinal materials planting, extraction, research and development, production, and sales.By the end of 2015, the company had nearly 10,000 employees, with a registered capital of 1.63382 million yuan.The company was listed on the Shanghai Stock Exchange in April 2004 with a stock code of 600572.
The company is registered in Lanxi City, Zhejiang Province. The management is headquartered in Hangzhou, Zhejiang Province. The industrial layout covers Hangzhou, Jinhua, Lanxi, and Jiangxi, Yunnan, Inner Mongolia, Sichuan, Guizhou, Heilongjiang and other places.The company owns Zhejiang Kang Enbei Traditional Chinese Medicine Co., Ltd., Zhejiang Jinhua Kang Enber Biopharmaceutical Co., Ltd., Yunnan Xitao Green Pharmaceutical Co., Ltd., Jiangxi Tianshikang Traditional Chinese Medicine Co., Ltd.Kang Enbei Pharmaceutical Co., Ltd., Shanghai Kang Enbei Pharmaceutical Co., Ltd., Zhejiang Kang En Bishe Pharmaceutical Research and Development Co., Ltd., Inner Mongolia Kang Enbei Pharmaceutical Co., Ltd.A number of wholly -owned and holding subsidiaries with large scale and strength.
The company is a key high -tech enterprise, national innovative enterprise, national innovative enterprise, national Chinese medicine top 50 enterprises, "five batches" key backbone enterprises in Zhejiang Province, Zhejiang Patent Demonstration Enterprise, National Chinese Medicine Modern Technology Industry (Zhejiang) base demonstrationEnterprises, the first batch of national intellectual property superior enterprises.After years of technological innovation and improvement, the companys research and development of drugs such as drug and cerebrovascular system drugs, urinary system drugs, anti -diabetes medication, respiratory system medication, digestive system medication, and anti -infectious drugs, as well as plant extraction and structural transformation, new type, new type, new typeMany aspects such as the application of the drug release system have accumulated many advantages.
The company has always attached great importance to the cultivation and protection of product brands and corporate brands. It has established a brand that consumers are familiar with and recognized in many areas such as urinary systems and cardiovascular and cerebrovascular systems, and "Kang Enbei", "Leading Kang", "Cherish the Mingming Mingming""" Tianbao Ning "," Alexin "," Jin Kang "," Jin Aokang "," Higao "," Tianbaokang "," Tians "," Tong Tong ", etc.Compared with similar competitive products, it shows a more prominent brand advantage and carries the sincere recognition of users.
In recent years, the company has actively promoted the integration of internal resources, improved the construction of marketing networks, improves the research and development, quality system and corporate culture, and firmly deployed pharmaceutical e -commerce business in the development strategy of "endogenous growth+investment and acquisition".All work has made good progress and results.
Looking forward to the future, the company will continue to adhere to the corporate mission of "doing their best for employees happiness and dedication to human health and love."Dedication of the society "Badas corporate rocks, with modern traditional Chinese medicine and botanical medicine industry as the core, develop chemical pharmaceutical and biopharmaceutical business.Expansion and extension with health services, and strive to establish a large health industry ecosystem based on the Internet and the entire industry chain!